Delaware |
|
001-34079
|
|
11-3516358
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
15245 Shady Grove Road, Suite
455 Rockville, MD
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
RNN
|
NYSE American
|
|
Emerging growth company ☐
|
Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
Item 7.01 |
Regulation FD Disclosure.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
Press release dated May 28, 2019.
|
Rexahn Pharmaceuticals, Inc.
|
||
By:
|
/s/ Douglas J. Swirsky
|
|
Douglas J. Swirsky
|
||
President and Chief Executive Officer
|
||
Dated: May 29, 2019 |